← All candidates
Two insider buys in the last year — $2.00M in all.
20 filings on record.
KYTXKyverna Therapeutics, Inc.
NasdaqGS · Healthcare · $448.98M
$7.26
-5.95% · Sep 15
Two insider buys in the last year — $2.00M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 2 buys● 1 sell◆ 13 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$448.98M
Float
39.7M
64% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Seidenberg Beth C
Bought $1000.0K on Dec 18 — 133,333 sh @ $7.50, held indirect, 15% of their stake.
1 of 1 position beat the S&P
10% owner
Westlake BioPartners Opportunity Fund I, L.P.
Bought $1000.0K on Dec 18 — 133,333 sh @ $7.50, held indirect, 15% of their stake.
1 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
13 more transactions on Pro →Context
Wall St
$30.40 avg target
+318.7% vs today · 5 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
4 of 4 quarters beat
Q2 '26−$0.63 act+$0.05
Q4 '25−$0.80 act+$0.06
Q3 '25−$0.85 act+$0.12
Q2 '25−$0.97 act+$0.07
Coverage
Kyverna Therapeutics Sinks 13%: Here’s Why24/7 Wall St. · 07-10Kyverna Therapeutics’ (KYTX) Insights into Stiff Person Syndrome and BeyondInsider Monkey · 07-09Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?Motley Fool · 06-08Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA
The file stays open
20 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice